To date, evidence shows that LRG1 is involved in pulmonary vascular dysfunction with increased expression seen in lung disease, including chronic obstructive pulmonary disease (COPD), interstitial pneumonia, airway inflammation in asthma, and active tuberculosis, with LRG1 levels serving as a biomarker for early diagnosis, progression, and prognosis (38, 66, 145–148). This evidence concerns the gene LRG1 and asthma.